Search
You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "pharma."
12 result(s) displayed (1 - 12 of 16)
Analysts and investors think the generics maker could command a higher price. Continue reading
Posted on July 17, 2012 1:12 PM
On the heels of the upholding of the Patient Protection and Affordable Care Act, HealthCare Royalty Partners' Clarke Futch discusses its impact on the healthcare and pharma space, as well as the opportunities for PE as a result. Continue reading
Posted on July 2, 2012 8:33 AM
On the heels of the upholding of the Patient Protection and Affordable Care Act, HealthCare Royalty Partners' Clarke Futch discusses its impact on the healthcare and pharma space, as well as the opportunities for PE as a result. Continue reading
Posted on July 2, 2012 4:00 AM
If it continues to release positive results from nearly two-dozen ongoing clinical trials for its cancer therapy Reolysin, Oncolytics Biotech Inc. could become an M&A target for a large pharmaceutical company looking to access innovative cancer treatments. Continue reading
Posted on November 16, 2011 9:27 AM
Stockholders vote against a deal they didn't like from the onset. Continue reading
Posted on October 24, 2011 11:41 AM
Par Pharmaceutical Cos. said Wednesday, Aug. 24, that it will buy privately held rival Anchen Pharmaceuticals Inc. for $410 million in cash to extend its portfolio of generic products.The deal is part of a rush by generic drug manufacturers to... Continue reading
Posted on August 24, 2011 11:16 AM
Movable Type search results powered by Fast Search
Ken deRegt will retire as head of fixed income at Morgan Stanley and be replaced by Michael Heaney and Robert Rooney. For other updates launch today's Movers & shakers slideshow.
Apax Partners offers $1.1 billion for Rue21, the same teenage fashion chain it took public in 2009. More video
